A Multi-Parametric and High-Throughput Platform for Host-Virus Binding Screens
Jan A. SchlegeliD, Bartłomiej PorębskiiD, Luca AndronicoiD, Leo HankeiD, Steven J. EdwardsiD, Hjalmar BrismariD, Ben MurrelliD, Gerald M. McInerneyiD, Óscar Fernández-CapetilloiD, Erdinç SezginiD
Abstract
Speed is key during infectious disease outbreaks. It is essential, for example, to identify critical host binding factors to the pathogens as fast as possible. The complexity of host plasma membrane is often a limiting factor hindering fast and accurate determination of host binding factors as well as high-throughput screening for neutralizing antimicrobial drug targets. Here we describe a multi-parametric and high-throughput platform tackling this bottleneck and enabling fast screens for host binding factors as well as new antiviral drug targets. The sensitivity and robustness of our platform was validated by blocking SARS-CoV-2 spike particles with nanobodies and IgGs from human serum samples. TeaserA fast screening platform tackling host-pathogen interactions.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 1.03
- Field percentile
- top 27%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High throughput screening identifies broad-spectrum Coronavirus entry inhibitors
S. Khan, E. O. Partuk, … O. Avinoam·bioRxiv·Dec 4, 2023
- Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2
C. Li, H. Zhou, … C.-N. Qian·bioRxiv·Dec 14, 2021
- SARS-CoV-2 comprehensive receptor profiling: mechanistic insight to drive new therapeutic strategies
S. M. Brockbank, R. Faba-Rodriguez, … J. Freeth·bioRxiv·Mar 11, 2021
- Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors.
Carly R. Cabel, Briana A. Guzman, … Curtis A. Thorne·Frontiers in Cell and Developmental BiologyPeer-reviewed·May 22, 2025
- In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum
S. Fiedler, M. A. Piziorska, … T. P. J. Knowles·bioRxiv·Dec 20, 2020
- A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
David Ezra Gordon, Gwendolyn Μ. Jang, … Natalia Jura·NaturePeer-reviewed·Apr 30, 2020